Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
8 participants
INTERVENTIONAL
2014-05-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.
NCT00940134
Oral Administration of Peptides; Absorption From Gastrointestinal Tract
NCT00468884
GLP-1 Signaling in Truncally Vagotomized Subjects
NCT02940184
Effects of Gut Peptides on Bone Remodeling
NCT03574064
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
NCT01043445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PYY infusion
IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
PYY1-36 infusion
Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
PYY1-36 + sitagliptin
Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
PYY3-36 infusion
0.8 pmol/kg/min infusion of PYY3-36.
placebo
Infusion of saline for 2 hrs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PYY1-36 infusion
Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
PYY1-36 + sitagliptin
Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
PYY3-36 infusion
0.8 pmol/kg/min infusion of PYY3-36.
placebo
Infusion of saline for 2 hrs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal BMI (18.5-25kg/m2)
Exclusion Criteria
* Gastric bypass
* Non-caucasian
* Height changes \>3 kg within last two months
* Hemoglobin \< 7.6 mmol/l
* Chronic disease
* Smoking
* Regularly use of medicine
* Drug abuse
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kirstine Nyvold Bojsen-Moeller
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Endocrinology, Hvidovre Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STKBM-PI14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.